
Alkermes (ALKS) Stock Forecast & Price Target
Alkermes (ALKS) Analyst Ratings
Bulls say
Alkermes PLC demonstrates a positive outlook due to the promising quantitative analyses supporting alixorexton's potential in treating narcolepsy type 1 (NT1), enhancing confidence in product efficacy. Specifically, alixorexton achieved rapid normalization in the Epworth Sleepiness Scale (ESS) at week 2, indicating effective performance in key wakefulness measures. Furthermore, the durability of this response during the open-label extension period underscores the likelihood of sustained benefits for patients, reinforcing the company’s strong position in addressing unmet medical needs.
Bears say
Alkermes PLC's outlook appears negative due to inconsistent results from its investigational product alixorexton, which displayed variability in the weekly cataplexy rate (WCR) with statistical significance only achieved at the 6 mg dose. The mixed outcomes in patient-reported endpoints may lead to uncertainty regarding the product's effectiveness, potentially diminishing investor confidence. Additionally, the reliance on proprietary technologies and third-party collaborations raises concerns about the company's ability to consistently deliver on unmet medical needs in competitive therapeutic markets.
This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.
Alkermes (ALKS) Analyst Forecast & Price Prediction
Start investing in Alkermes (ALKS)
Order type
Buy in
Order amount
Est. shares
0 shares